<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597868</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH15003</org_study_id>
    <nct_id>NCT02597868</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)</brief_title>
  <official_title>A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Tumor Hospital of Jiangsu Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-sites study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine
      therapy, in metastatic breast cancer patients with HR-positive &amp; HER2-negative after
      capecitabine-base chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      capecitabine-base chemotherapy must be first-line chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the time elapsed between enrolling and tumor progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate(CBR)</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>the response is CR+PR+SD â‰¥ 24 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>From date of enrolling until the date of death from any cause, assessed up to 3 years</time_frame>
    <description>the time elapsed between enrolling and death from any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Grade 3/4 adverse events</measure>
    <time_frame>From date of enrolling until the date of 1 month of stop treatment, assessed up to 3 years</time_frame>
    <description>Number of Participants with Grade 3/4 Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>QOL</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>change from enrolling to progression disease or death according EORTC QLQ-C30 and EORTC BR23</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endocrine therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endocrine therapy</intervention_name>
    <description>endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.</description>
    <arm_group_label>endocrine therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  The age is Above 18 years of age, &lt;70 years old

          -  HR-positive &amp; HER2-negative

          -  Metastatic breast cancer,incurable.

          -  No prior chemotherapy for metastatic recurrence, if there is disease progression
             within 6 months after the end of the adjuvant chemotherapy, adjuvant chemotherapy as
             first-line treatment for metastatic lesions

          -  Eastern Cooperative Oncology Group performance status (ECOG PS)=0~1

          -  The basic function of normal bone marrow

          -  Functions of liver and kidney is normal

          -  Expectation of life is more than 3 months

          -  Agreed to take contraceptive measures during treatment

        Exclusion Criteria:

          -  Previous toxicity was not recovered to 0-1 degrees

          -  Central nervous system metastasis

          -  Pregnancy or lactation

          -  There are uncontrolled infection, myocardial infarction, thrombosis, etc.

          -  There are uncontrolled chronic diseases such as diabetes, hypertension, peptic ulcer,
             chronic hepatitis, mental disease;

          -  Researchers believe that is not suitable for the study

          -  Patients with other malignant tumor history, except the healed skin basal cell
             carcinoma and carcinoma of uterine cervix;

          -  Bilateral breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojia Wang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojia - wang, PHD</last_name>
    <phone>86 13906500190</phone>
    <email>wxiaojia0803@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Huang, Doctor</last_name>
    <phone>86 13588048995</phone>
    <email>huang_jian22@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia Wang, PHD</last_name>
      <phone>86 13906500190</phone>
      <email>wxiaojia0803@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Huang, Doctor</last_name>
      <phone>86 13588048995</phone>
      <email>huang_jian22@aliyun.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaojia Wang, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>March 26, 2016</last_update_submitted>
  <last_update_submitted_qc>March 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>therapy</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

